nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Extended-Release Oral Suspension Approved for ADHD
October 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. Adzenys ER is an orange flavored, once-daily extended-release liquid that does not need to be reconstituted or refrigerated and may be taken with or without food. It will be available in early 2018. Adzenys ER is considered bioequivalent to Adderall XR (dextroamphetamine and amphetamine extended-release capsules). Adzenys ER is Neos Therapeutics’ third ADHD extended-release medication to gain FDA approval. Other ADHD extended-release medications from Neos Therapeutics include the two extended-release orally-disintegrating tablets: Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate).

     Additional Resources:

Tips and Pearls
Stimulants for ADHD

Multiple new formulations of stimulant medications have recently been approved for ADHD.

Reference:

>> Neos Therapeutics receives U.S. FDA approval of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older [press release]. Neos Therapeutics. September 15, 2017